This investment will help the inventor of the IUB™ intrauterine platform to boost its expansion and increase manufacturing capacity
Chemo Group is already marketing the spherical copper intrauterine device in several European countries
Chemo India Formulations located in Hyderabad, have required an initial investment of around ₹100 crores (USD 16 million)
Specialized in the development and manufacture of oral solid dosage forms, including tablets, caplets, hard gelatin capsules and pellets
On August 29th, the U.S. Food and Drug Administration (FDA) approved Chemo Research’s New Drug Application (NDA) for benznidazole. This is the first drug ever approved by the FDA to treat Chagas disease.
A new edition of the #ChagasChallenge, promoted by Mundo Sano and the multinational pharmaceutical company Chemo Group, has now begun. For the third time, this charity adventure will be supported by the athlete Chema Martinez, who will hang up her running shoes for a few days to cover the 750 kilometres that separate Madrid from the Portuguese capital by bike.
Our Group will once again be present at this key trade fair for the sector, this time to be held in Frankfurt from 24 to 26 October. At this event, which presents the latest trends of a global and constantly evolving industry, Chemo will be present with the latest innovations of its full range of active principles and finished pharmaceutical forms. Just as every year, a high number of visitors are expected, possibly exceeding 42,000 professionals from 153 countries. Our Group can be found at stand 6.0D20.
The Chemo pharmaceutical group has just announced that it has acquired a stake in the US company Babyscripts, a virtual care platform for women during pregnancy, with the aim of helping it to consolidate its presence The United States and boost its expansion in Europe, starting with Spain. Together with the Chemo Group, Ysios Capital, a Spanish investment management company in the life sciences sector has led a funding round of 5.5 million euros which, in addition to the pharmaceutical multinational, has been joined by strategic investors such as CG Health Ventures, Aurora Health Care Ventures, and P5 Health Ventures.
The pharmaceutical multinational Chemo Group has just announced that it is opening two new plants that will produce injectable medicines. With these new facilities, the company now has a total of six plants in this country, employing more than 1,600 people between all of its work centres. The new plants, Universal Farma (Azuqueca de Henares, Guadalajara) with over 8,000 m2, and Farmalan (Villaquilambre, León) with 3,600 m2, have been prepared for the manufacture and final packaging of injectable medicines and are equipped with the sector's latest technology.
The pharmaceutical group Chemo has just launched a programme to help implement innovative health projects and to boost projects that are already up and running. With the name #ChemoStart, it is looking for start-ups that specialise in innovative solutions for patients, predictive analytics, biosensors or genomics, amongst others. For this, they have launched a microsite that allows researchers and entrepreneurs who wish to register their projects easily and participate in this initiative.
Exeltis Spain, a company that belongs to the Chemo Group, has acquired Juste's Pharma Unit in an operation that includes the sourcing, research, manufacture (through third parties), promotion and sale of pharmaceutical products for Gynaecology, the Central Nervous System and Primary Care, featuring drugs used to treat insomnia, depression and epilepsy. In the words of Exeltis's General Manager in Spain and Portugal, Alberto Fábregas: “The aim of this operation is to strengthen and increase the company's range of products, and to consolidate Exeltis's presence in the Iberian market, by incorporating the expertise and professionals of Juste's Pharma Unit”.
As a business adhering to the Responsible Care programme, Chemo Group has recently been authorised to use the CSR-Corporate Social Responsibility branding after fulfilling all the necessary requirements. This stamp guarantees Chemo Group’s commitment to Corporate Social Responsibility. The initiative aims to provide companies within this programme with visible recognition that certifies their commitment to CSR policies.
With more than 22 years of implementation in Spain, Responsible Care is the international voluntary initiative of the chemical sector for the continuous improvement of Safety, Health and Environmental Protection in all its operations, in accordance with the principles of Sustainable Development and The CSR. Currently more than 60% of Spanish chemical production is carried out in companies affiliated with Responsible Care.